[go: up one dir, main page]

AR002282A1 - Polipeptidos utiles para detectar y/o tratar infestaciones con t. cruzi, composiciones farmaceuticas formuladas con dichos polipeptidos; equipos queincluyen dichos polipeptidos para el diagnostico de dichas infecciones, dna, vectores y celulas recombinantes transformadas con dicho dna. - Google Patents

Polipeptidos utiles para detectar y/o tratar infestaciones con t. cruzi, composiciones farmaceuticas formuladas con dichos polipeptidos; equipos queincluyen dichos polipeptidos para el diagnostico de dichas infecciones, dna, vectores y celulas recombinantes transformadas con dicho dna.

Info

Publication number
AR002282A1
AR002282A1 ARP960101762A AR10176296A AR002282A1 AR 002282 A1 AR002282 A1 AR 002282A1 AR P960101762 A ARP960101762 A AR P960101762A AR 10176296 A AR10176296 A AR 10176296A AR 002282 A1 AR002282 A1 AR 002282A1
Authority
AR
Argentina
Prior art keywords
polypeptides
dna
infestations
cruzi
vectors
Prior art date
Application number
ARP960101762A
Other languages
English (en)
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AR002282A1 publication Critical patent/AR002282A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se trata de nuevos péptidos para tratar y/o detectar infestaciones con T. Cruzi, caracterizados porque comprenden, al menos 7 restos consecutivos de lafracción SEQ ID NO: 1 entre la lisina al resto 137 y la alanina al resto 247, o variantesantigén icas de los mismos, que difieren solamente en sustituciones omodificaciones conservativas, con la condición de que el polipéptido no contenga mas de cinco restos consecutivos de la porción SEQ ID NO: 1 entre elaminoácido 1 y elaminoácido 136 . También se proponen composiciones farmacéuticas para dichas infestaciones y equipos para el diagnóstico de dichasinfestaciones. Se incluyen además células transformadas con vectores que comprenden el DNAcorrespondiente a dichos polipéptidos.
ARP960101762A 1995-03-14 1996-03-15 Polipeptidos utiles para detectar y/o tratar infestaciones con t. cruzi, composiciones farmaceuticas formuladas con dichos polipeptidos; equipos queincluyen dichos polipeptidos para el diagnostico de dichas infecciones, dna, vectores y celulas recombinantes transformadas con dicho dna. AR002282A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/403,379 US5756662A (en) 1995-03-14 1995-03-14 Compounds and methods for the detection of T. cruzi infection

Publications (1)

Publication Number Publication Date
AR002282A1 true AR002282A1 (es) 1998-03-11

Family

ID=23595554

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101762A AR002282A1 (es) 1995-03-14 1996-03-15 Polipeptidos utiles para detectar y/o tratar infestaciones con t. cruzi, composiciones farmaceuticas formuladas con dichos polipeptidos; equipos queincluyen dichos polipeptidos para el diagnostico de dichas infecciones, dna, vectores y celulas recombinantes transformadas con dicho dna.

Country Status (13)

Country Link
US (2) US5756662A (es)
EP (1) EP0815450B1 (es)
JP (1) JPH11502923A (es)
AR (1) AR002282A1 (es)
AT (1) ATE220797T1 (es)
AU (1) AU5362696A (es)
BR (1) BR9607531A (es)
CA (1) CA2215104A1 (es)
DE (1) DE69622385T2 (es)
DK (1) DK0815450T3 (es)
ES (1) ES2180754T3 (es)
PT (1) PT815450E (es)
WO (1) WO1996029605A2 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756662A (en) * 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
BR9503451A (pt) * 1995-07-26 1997-09-30 Mendes Rodolfo Pereira Processo de preparação de um antígeno derivado de um mocroorganismo causador de doença infecciosa e/ou parasitária processo de preparação de um antígeno de T cruzi antígeno derivado de midroorganismo causador de doença infecciosa e/ou parasitária antígeno derivado de T cruzi causador de doença de chagas composição a base de um antígeno derivado de microorganismo causador de doença infecciosa e/ou parasitária composição a base de antígeno de T cruzi utilização do antígeno derivado de microorganismo causador de doença infecciosa e/ou parasitária em testes sorológicos e vacinas utilização de antigeno derivado de T cruzi causador de doença de chagas em teste sorológico e vacinas processo para detecção de anticorpos anti antigeno de microorganismo causador de doença infecciosa e/ou parasitária e kit para sorodiagnóstico confirmatório para doença infecciosa e/ou parasitária
US6419933B1 (en) * 1995-11-14 2002-07-16 Corixa Corporation Compounds and methods for the detection and prevention of T.cruzi infection
US5916572A (en) * 1995-11-14 1999-06-29 Corixa Corporation Compounds and methods for the detection and prevention of T. cruzi infection
US6054135A (en) * 1996-11-14 2000-04-25 Corixa Compounds and methods for the detection and prevention of T. cruzi infection
US6228372B1 (en) 1997-04-15 2001-05-08 Corixa Corporation Compounds and methods for the detection and prevention of T. cruzi infection
EP0966537B1 (en) 1997-03-11 2009-01-07 Stichting Dienst Landbouwkundig Onderzoek Fasciola hepatica vaccines
US6699722B2 (en) 2000-04-14 2004-03-02 A-Fem Medical Corporation Positive detection lateral-flow apparatus and method for small and large analytes
CA2498604A1 (en) * 2002-09-20 2004-04-01 Akzo Nobel N.V. Live antenuated parasite vaccine
JP4884367B2 (ja) 2004-02-24 2012-02-29 アボット・ヘルスケア・プロダクツ・ベスローテン・フェンノートシャップ 神経疾患を発症する危険性を決定するための方法
US7888135B2 (en) * 2004-04-23 2011-02-15 University Of Georgia Research Foundation, Inc. Diagnostic assay for Trypanosoma cruzi infection
WO2009017736A1 (en) * 2007-07-30 2009-02-05 University Of Georgia Research Foundation Inc. Diagnostic assay for trypanosoma cruzi infection
JP5419131B2 (ja) 2005-12-12 2014-02-19 エーシー イミューン ソシエテ アノニム 治療的特性を有するβ１〜４２特異的モノクローナル抗体
US7833534B2 (en) 2006-04-10 2010-11-16 Infectious Disease Research Institute Compounds and methods for diagnosis and treatment of leishmaniasis
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
MY165105A (en) 2006-07-14 2018-02-28 Ac Immune Sa Humanized antibody against amyloid beta
US7749717B2 (en) * 2006-10-19 2010-07-06 Abbott Laboratories Methods for the detection and diagnosis of Trypanosoma cruzi infection
SG173409A1 (en) 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
MX2009013503A (es) 2007-06-12 2010-01-27 Genentech Inc Anticuerpo monoclonal anti-amiloide-beta.
WO2008156622A1 (en) 2007-06-12 2008-12-24 Ac Immune S.A. Humanized antibodies to amyloid beta
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
WO2009048538A2 (en) 2007-10-05 2009-04-16 Genentech, Inc. Humanized antibody
PL2238166T3 (pl) 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
JP5611834B2 (ja) * 2007-12-27 2014-10-22 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 抗Ｔ．ｃｒｕｚｉ抗体及び使用方法
US20090325204A1 (en) * 2008-06-27 2009-12-31 Reed Steven G Compounds and methods for diagnosis and treatment of chagas disease
ES2628743T3 (es) 2008-07-03 2017-08-03 Infectious Disease Research Institute Proteínas de fusión y su uso en el diagnóstico y tratamiento de la leishmaniasis
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
EP2377860A1 (en) 2010-04-16 2011-10-19 AC Immune S.A. Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
PH12012502079A1 (en) 2010-04-16 2013-02-11 Ac Immune Sa Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
SI2625198T1 (sl) 2010-10-07 2015-11-30 Ac Immune S.A. Epfl Innovation Park Protitelesa, ki prepoznavajo fosfo-tau
EP2632434B1 (en) 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
AR092779A1 (es) 2011-10-07 2015-05-06 Ac Immune Sa Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau
BR112014024769A2 (pt) 2012-04-05 2017-12-12 Ac Immune Sa anticorpo humanizado tau
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
JP6826367B2 (ja) 2012-08-31 2021-02-03 ストロ バイオファーマ インコーポレーテッド アジド基を含む修飾アミノ酸
BR112015023262B8 (pt) 2013-03-15 2024-02-06 Ac Immune Sa Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
KR102321172B1 (ko) 2013-09-05 2021-11-05 에이비2 바이오 에스에이 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ)
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CA2972689A1 (en) 2015-03-05 2016-09-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
WO2017218698A1 (en) 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
GB201807367D0 (en) 2018-05-04 2018-06-20 Univ Newcastle Biomarker
EP4114852A1 (en) 2020-03-03 2023-01-11 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
US20230173021A1 (en) 2020-05-06 2023-06-08 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) In Respiratory Diseases
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
EP4486367A1 (en) 2022-03-04 2025-01-08 AB2 Bio SA Il-18 binding protein (il-18bp) in the treatment of vexas
WO2024006563A1 (en) 2022-07-01 2024-01-04 Sutro Biopharma, Inc. Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same
WO2024044780A1 (en) 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024098023A2 (en) 2022-11-04 2024-05-10 Sutro Biopharma, Inc. Interferon alpha polypeptides and conjugates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870006A (en) * 1986-07-24 1989-09-26 Codon Antigenic material for a chagas' disease detection system
WO1990002564A1 (en) * 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi
BR9006039A (pt) * 1990-11-28 1992-07-14 Fundacao Oswaldo Cruz Processo para preparacao de antigeno conjugado a atividade enzimatica,composicao a base de conjugado enzima-antigeno para utilizacao em diagnostico imunologico e kits de diagnostico imunologico da doenca de chagas a base da dita composicao,para aplicacao individual e/ou em inqueritos epidemiologicos
US5304371A (en) * 1992-02-14 1994-04-19 Lasys Corporation Peptide for diagnosing and immunizing against T. cruzi infection
TW246717B (es) * 1992-07-10 1995-05-01 Abbott Lab
US5756662A (en) * 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection

Also Published As

Publication number Publication date
EP0815450B1 (en) 2002-07-17
PT815450E (pt) 2002-12-31
ATE220797T1 (de) 2002-08-15
DE69622385D1 (de) 2002-08-22
CA2215104A1 (en) 1996-09-26
US5756662A (en) 1998-05-26
AU5362696A (en) 1996-10-08
DE69622385T2 (de) 2003-03-06
WO1996029605A2 (en) 1996-09-26
ES2180754T3 (es) 2003-02-16
BR9607531A (pt) 1998-01-06
WO1996029605A3 (en) 1996-11-21
EP0815450A2 (en) 1998-01-07
US5942403A (en) 1999-08-24
JPH11502923A (ja) 1999-03-09
DK0815450T3 (da) 2002-10-28
MX9707020A (es) 1998-06-30

Similar Documents

Publication Publication Date Title
AR002282A1 (es) Polipeptidos utiles para detectar y/o tratar infestaciones con t. cruzi, composiciones farmaceuticas formuladas con dichos polipeptidos; equipos queincluyen dichos polipeptidos para el diagnostico de dichas infecciones, dna, vectores y celulas recombinantes transformadas con dicho dna.
ATE368053T1 (de) Antimikrobielle peptide
EP0793675A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING PHENOMENAL RELATIONSHIPS WITH MEMBRANE FUSIONS, INCLUDING THE TRANSMISSION OF HIV
AR017510A1 (es) Polinucleotido aislado o recombinante, vector de expresion, celula huesped, metodo para preparar un polipeptido antigenico, metodo y equipo para ladeteccion de un polinucleotido, compuesto de union, metodo de empleo del compuesto de union, polipeptido antigenico aislado o substancialmente puro, ymet
DE3262006D1 (en) Radiolabelled peptides derived from crosslinked fibrin for locating thrombi and injectable compositions thereof
DK0479948T3 (da) Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder
PT1218751E (pt) Epitopo de diagnostico e terapeutico e planta transgenica
ES2196031T3 (es) Derivados peptidicos terapeutico.
NO990533L (no) GnRH-leukotoksin kimµrer
EP0333356A3 (en) Hirudin peptides
DK0863155T3 (da) Suppression af T-celle-proliferation under anvendelse af peptidfragmenter af myelin basisk protein
AR020066A1 (es) Un polipeptido purificado, util para prevenir la tuberculosis y las composiciones farmaceuticas que contienen dichos polipeptidos y los polinucleotidos quelos codifican
AR006813A1 (es) Peptidos consistentes en 16 a 55 residuos de aminoacido, composicion farmaceutica que comprende a por lo menos uno de dichos peptidos, metodo dediagnostico para la deteccion de celulas t auto-reactivas activadas que utiliza a por lo menos uno de tales peptidos y equipo para pruebas utilizado en dicho
DK525384D0 (da) Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
EP1539800A4 (en) DIMERS OF THROMBEPEPTIDE DERIVATIVES
ATE161543T1 (de) Aminoterminale prokollagen 1(i) peptide
Roustan et al. Structural variations in actins. A study of the immunological reactivity of the N-terminal region
ATE98962T1 (de) Menschliche rhinoviruspeptide.
DK1612555T3 (da) Kryptiske peptider til anvendelse til at inducere immunologisk tolerance
ATE162850T1 (de) Phospholipase c inhibitierendes peptid
Bergamo et al. Two rat middle-piece coating antigens are lost upon in vitro capacitation
ATE382059T1 (de) Neue humane androgenrezeptor-varianten
DK200200302A (da) Rekombinante polypeptider omfattende aminosyresekvensen af moden vævsfaktorinhibitor (TFI), polypeptidfragmenter deraf, ekspressionsvektorer der koder for disse, værtsceller transformeret dermed, og fremgangsmåde til fremstilling af et ........

Legal Events

Date Code Title Description
FC Refusal